Endo international, AngioDynamics Lead Biotech Movers

Endo International (ENDP) shares slipped more than 5% ahead of the opening bell Friday after trading positively on Thursday. The company announced on Wednesday that it planned to refinance an existing credit agreement, and that it would use the proceeds to pay back existing loans.  The company's shares spiked 3% to $11.27 apiece Thursday, but then fell in pre-market trading to $10.69.

AngioDynamics (ANGO) was also falling ahead of the opening bell. The company's shares fell 4% ahead of market's open Friday, hitting $16.20 apiece on news of a public offering by certain of its stockholders. The company is offering 2.35 million shares of its common stock at $16.20 per share. AngioDynamics focuses on vascular disease. The company barely moved during normal trading hours Thursday, gaining just 0.5%.

Trevena (TRVN) meanwhile continued to gain ahead of normal trading hours Friday thanks to positive phase three data it reported Thursday. The company's shares were up nearly 3% ahead of market's open, after a day of gaining nearly 5%. Trevena shares hovered around $3.50 apiece as the market opened.

Novocure (NVCR) was also gaining ahead of market's open. The company's shares were up 2% ahead of market's open, hitting $11.20 apiece. This was after a day of trading positively, gaining nearly 7%.

More from Stocks

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Abercrombie & Fitch CEO: We Aren't the Same Abercrombie You Once Knew

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Amazon Wants to Use Your Car as a Mobile Warehouse - Here's What That Could Mean

Chipotle's New CEO Has Set its Path for Redemption

Chipotle's New CEO Has Set its Path for Redemption

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

TheStreet Is About to Hold the BEST Institutional Investor Conference of 2018

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced

Twitter's Turnaround Continues but Investors Don't Seem Entirely Convinced